雄激素受体通过微小RNA-1介导下调抑制TCF7并参与前列腺癌雄激素剥夺抵抗的发生
本研究探讨转录因子7(TCF7)在前列腺癌去势抵抗中的作用及雄激素受体(AR)信号失活时TCF7被诱导的分子机制。通过临床数据集、组织样本、前列腺癌细胞系及小鼠异种移植模型证实,AR信号部分通过miR-1介导下调抑制TCF7,TCF7过表达或miR-1功能破坏促进雄激素非依赖性增殖,TCF7失调赋予生存优势及雄激素剥夺抵抗。
要点
- AR信号部分通过miR-1介导的下调抑制TCF7。
- TCF7具有致癌特性并削弱miR-1的抑瘤效应。
- TCF7过表达或miR-1功能破坏促进雄激素非依赖性增殖。
核心结论
- AR-miR-1轴负向调控新致癌因子TCF7,TCF7失调促进生存优势及雄激素剥夺抵抗,提示其作为去势抵抗性前列腺癌治疗靶点的潜力。
研究设计与样本
- 分析临床数据集寻找AR-miR-1信号在TCF/LEF家族中的潜在靶点,利用组织样本验证关系,并在前列腺癌细胞系和小鼠异种移植模型中展示分子机制与生物学功能。
主要发现
- AR信号部分通过miR-1介导的下调抑制TCF7。
- TCF7表现出致癌特性并削弱miR-1的肿瘤抑制效应。
- TCF7过表达或miR-1功能破坏促进雄激素非依赖性增殖。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Resistance to androgen deprivation therapy (ADT) represents a key step in the malignant progression of prostate cancer, and mutation to androgen receptor (AR) is one major driver to an androgen-independent phenotype. However, alternative oncogenic pathways that bypass AR signaling have emerged as an important mechanism promoting resistance to ADT. It is known that AR activation can prevent the interaction between β-catenin and T cell factor/lymphoid enhancer-binding factor (TCF/LEF) family, inhibiting the Wnt signaling pathway. The aim of this study was to determine the role of transcription factor 7 (TCF7), a transcription factor best known as a Wnt effector that forms a complex with β-catenin, in the development of advanced prostate cancer. We further investigated the molecular mechanisms by which TCF7 is induced when AR signaling is inactivated. METHODS: A novel AR signaling pathway that induces microRNA-1 (miR-1) to suppress metastatic prostate cancer was recently demonstrated (AR-miR-1 signaling axis), and its regulation of Wnt signaling was explored in the current study. Clinical data sets were analyzed for potential targets of AR-miR-1 signaling in the TCF/LEF family, and tissue samples were utilized to validate the relationship. The molecular mechanism and biological functions were demonstrated in prostate cancer cell lines and a mouse xenograft model. RESULTS: We demonstrated a molecular mechanism of AR signaling suppressing TCF7 partly through miR-1-mediated downregulation. TCF7 exhibited oncogenic properties and compromised the tumor-suppressive effects of miR-1. Our results also showed that overexpression of TCF7 or disruption of miR-1 function promoted androgen-independent proliferation. CONCLUSIONS: We demonstrated that the AR-miR-1 axis negatively regulates the novel oncogenic factor, TCF7. Dysregulation of TCF7 promoted a survival advantage and resistance to androgen deprivation, suggesting its therapeutic potential for castration-resistant prostate cancer.
引用
- Siu MK, Chen WY, Tsai HY, et al. TCF7 is suppressed by the androgen receptor via microRNA-1-mediated downregulation and is involved in the development of resistance to androgen deprivation in prostate cancer. Prostate Cancer Prostatic Dis. 2017. PMID: 28220803. doi:10.1038/pcan.2017.2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。